Novartis Investigative Site

Montpellier, Herault 34059

0 studies enrolling now · 10 studies all time

What they study most

Asthma, Chronic Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, PIK3CA-Related Overgrowth Spectrum (PROS), Pulmonary Disease, Chronic Obstructive

Studies at this site

• Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A — Stopped early
• This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. — Stopped early
• Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients — Completed
• Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib — Completed
• Systemic Corticosteroids Avoidance Study in Severe Asthma Patients — Stopped early
• Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma — Completed
• Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment — Stopped early
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. — Completed
• Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction — Completed